Has Haig Goenjian, MD received payments from drug or device companies?

Yes. Drug and device makers reported $6,298,627 in general payments to Haig Goenjian, MD across 352 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Haig Goenjian, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Haig Goenjian, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Haig Goenjian, MD

Psychiatry · Long Beach, CANPI 1831487438

Payments from drug & device makers

$6,298,627in general payments, 2019–2025

Across 352 payments — averaging $17,894 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1.6M
Sumitomo Pharma America, Inc.$1.4M
Sanofi Pasteur Inc.$719K
Bioxcel Therapeutics, Inc.$685K
E.r. Squibb & Sons, L.L.C.$634K
Otsuka Pharmaceutical Development & Commercialization, Inc.$550K
plus $780K from 15 others

$2,471in research payments, 2019–2025

Across 12 payments — averaging $205.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi Pasteur Inc.$2K

What the payments were for

Consulting fees$7,75034%
Speaking & faculty fees$10,25044%
Travel & lodging$2,64311%
Food & beverage$2,34810%
Education$470%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	60	$1,551,213
Sumitomo Pharma America, Inc.	44	$1,379,267
Sanofi Pasteur Inc.	8	$718,948
Bioxcel Therapeutics, Inc.	14	$684,880
E.r. Squibb & Sons, L.L.C.	7	$633,742
Otsuka Pharmaceutical Development & Commercialization, Inc.	45	$550,396
Pfizer	24	$526,581
Sunovion Pharmaceuticals Inc.	10	$65,688
Boehringer Ingelheim	7	$50,462
Sage Therapeutics, LLC	15	$42,120
Boehringer Ingelheim International GmbH	40	$31,313
Vanda Pharmaceuticals Inc.	5	$26,900
Neurocrine Biosciences, Inc.	17	$13,631
Johnson & Johnson	33	$11,479
Alkermes, Inc.	9	$5,557
Merck	1	$4,293
Jazz Pharmaceuticals Inc.	2	$1,825
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	8	$161
Axsome Therapeutics, Inc.	1	$123
Indivior Inc.	1	$28
Otsuka America Pharmaceutical, Inc.	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ARISTADA$20,942
SPRAVATO$11,033
ARISTADA INITIO$5,235
Auvelity$123
COBENFY$102

How this compares

$6,298,627 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Medicare billing

Part B allowed, 2024

$59,173

Medicare patients

Services billed

645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Risperidone OdtRisperidone	44	$12,516
Olanzapine OdtOlanzapine	92	$7,167
Aripiprazole	74	$4,033
Fluphenazine Hcl	17	$3,768
Clozapine	40	$3,765
Divalproex Sodium	95	$2,456
Risperidone	156	$2,199
Olanzapine	97	$1,994
Quetiapine Fumarate	95	$1,556
AmantadineAmantadine Hcl	13	$1,088
Trazodone Hcl	67	$759
Ziprasidone Hcl	19	$643
Sertraline Hcl	113	$576
Quetiapine Fumarate ErQuetiapine Fumarate	25	$557
Benztropine Mesylate	39	$547

Paid to pharmacies, not to this prescriber.

Other psychiatry in Long Beach

Armen GoenjianLong Beach$5.3M
Christopher ReistLong Beach$2.9M
Elly LeeIrvine$49.8M
Daniel ChuehOrange$17.9M
Eric ChavezSan Diego$15.5M
Lara ShirikjianTorrance$12.6M
John DuffySanta Ana$12M
Marina BusselPlaya Vista$12M
Sherry SoefjeOceanside$11.9M
Steven MacinaHuntington Beach$11.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →